Wednesday, May 08, 2019 7:04:22 AM
Actually I trust more in the report produced by IQVIA..."This survey used a combination of interviews, market data and product usage reports to create a detailed outlook for HemoStyp's revenue potential assuming, among other factors, the receipt of FDA approval for Class III surgical applications." Trust in the investment banker Societe Generale recommending and reaching out to IQVIA and spending every bit of $100k for a report that brings offers in sooner (already on the table IMO) then later! The NDA's are signed and under review IMO!
Recent UEEC News
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 05/22/2026 08:05:56 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/15/2026 08:00:44 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 05/15/2026 04:15:15 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 05/11/2026 08:05:55 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 04/15/2026 09:11:17 PM
- Form S-1 - General form for registration of securities under the Securities Act of 1933 • Edgar (US Regulatory) • 01/15/2026 10:01:16 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/22/2025 10:20:37 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 07:44:29 PM
- Life Sciences Virtual Investor Forum: Presentations Now Available for Online Viewing • GlobeNewswire Inc. • 09/18/2025 12:35:00 PM
- United Health Products to Present at the Life Sciences Virtual Investor Forum September 18th • GlobeNewswire Inc. • 09/16/2025 08:10:32 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 07:41:41 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/16/2025 01:53:36 PM
